102 related articles for article (PubMed ID: 9568174)
21. Serum CD44 splice variants in cervical cancer patients.
Kainz C; Tempfer C; Winkler S; Sliutz G; Koelbl H; Reinthaller A
Cancer Lett; 1995 Apr; 90(2):231-4. PubMed ID: 7537626
[TBL] [Abstract][Full Text] [Related]
22. Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer.
Gadducci A; Marrai R; Baicchi U; Gagetti O; Facchini V; Genazzani AR
Gynecol Oncol; 1996 May; 61(2):215-7. PubMed ID: 8626135
[TBL] [Abstract][Full Text] [Related]
23. Hyaluronate binding assay study of transfected CD44 V4-V7 isoforms into the human gastric carcinoma cell line SC-M1.
Harn HJ; Shen KL; Liu CA; Ho LI; Yang LS; Yueh KC
J Pathol; 1998 Mar; 184(3):291-6. PubMed ID: 9614382
[TBL] [Abstract][Full Text] [Related]
24. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer.
Masson D; Denis MG; Denis M; Blanchard D; Loirat MJ; Cassagnau E; Lustenberger P
Br J Cancer; 1999 Aug; 80(12):1995-2000. PubMed ID: 10471052
[TBL] [Abstract][Full Text] [Related]
25. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer.
van de Lande J; Davelaar EM; von Mensdorff-Pouilly S; Water TJ; Berkhof J; van Baal WM; Kenemans P; Verheijen RH
Gynecol Oncol; 2009 Jan; 112(1):119-25. PubMed ID: 19007978
[TBL] [Abstract][Full Text] [Related]
26. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
27. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
[TBL] [Abstract][Full Text] [Related]
28. CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB.
Bouda J; Boudova L; Hes O; Havir M; Tempfer C; Kohlberger P; Svoboda T; Rokyta Z; Speiser P
Anticancer Res; 2005; 25(1B):617-22. PubMed ID: 15816636
[TBL] [Abstract][Full Text] [Related]
29. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
30. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
31. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
Peng XP; Li JD; Li MD; Ye XM; Yan WC
Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
[TBL] [Abstract][Full Text] [Related]
32. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
33. Concentration of soluble CD44 standard and soluble CD44 variant V5 in the serum of patients with malignant bone tumors.
Holzer G; Kittl E; Pfandelsteiner T; Trieb K; Kotz R
Med Pediatr Oncol; 2003 Jan; 40(1):64-5. PubMed ID: 12426692
[No Abstract] [Full Text] [Related]
34. Human mast cells express the hyaluronic-acid-binding isoform of CD44 and adhere to hyaluronic acid.
Fukui M; Whittlesey K; Metcalfe DD; Dastych J
Clin Immunol; 2000 Mar; 94(3):173-8. PubMed ID: 10692236
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of RCAS1 as a biomarker of uterine cancer.
Sonoda K; Miyamoto S; Hirakawa T; Yagi H; Yotsumoto F; Nakashima M; Watanabe T; Nakano H
Gynecol Oncol; 2006 Dec; 103(3):924-31. PubMed ID: 16842844
[TBL] [Abstract][Full Text] [Related]
36. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.
Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714
[TBL] [Abstract][Full Text] [Related]
37. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Prontera C; Facchini V; Bianchi R; Genazzani AR
Gynecol Oncol; 1998 Jul; 70(1):111-4. PubMed ID: 9698485
[TBL] [Abstract][Full Text] [Related]
38. Soluble CD44 splice variants in metastasizing human breast cancer.
Martin S; Jansen F; Bokelmann J; Kolb H
Int J Cancer; 1997 Aug; 74(4):443-5. PubMed ID: 9291436
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
40. Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression.
Lu D; Tawfik O; Pantazis C; Hobart W; Chapman J; Iczkowski K
Gynecol Oncol; 1999 Oct; 75(1):84-90. PubMed ID: 10502431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
